Drug Trial Radar · NCT02554773
An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Sep 18, 2015
Primary completion
Mar 21, 2023
Study completion Mar 21, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the long-term safety and tolerability of fitusiran in male patients with moderate or severe hemophilia A or B Secondary Objectives: * To investigate the long-term efficacy of fitusiran * To characterize the safety and efficacy of concomitantly administered Factor VIII (FVIII), Factor IX (FIX) or bypassing agents (BPA) and fitusiran for treatment of bleeding episodes * To assess changes in health-related quality of life (QOL) over time * To characterize antithrombin (AT) reduction and thrombin generation (TG) increase * To characterize the pharmacokinetics (PK) of fitusiran
Conditions
- Hemophilia A
- Hemophilia B
Interventions
Fitusiran (SAR439774)Drug
Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
- Number of Participants With Potentially Clinically Significant Abnormality (PCSA): HematologyTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
- Number of Participants With Potentially Clinically Significant Abnormality: Clinical ChemistryTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
- Number of Participants With Potentially Clinically Significant Abnormality: UrinalysisTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
- Number of Participants With Potentially Clinically Significant Abnormality: Vital SignsTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
- Number of Participants With Potentially Clinically Significant Abnormality: Electrocardiogram (ECG)Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
- Number of Participants With Potentially Clinically Significant Abnormality: Physical ExaminationTime frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Ann Arbor, Michigan
Clinical Trial Site
Pittsburgh, Pennsylvania
Clinical Trial Site
Plovdiv, Bulgaria
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Kirov, Russia
Clinical Trial Site
Moscow, Russia
Clinical Trial Site
Zurich, Switzerland
Clinical Trial Site
Basingstoke, United Kingdom
Clinical Trial Site
Glasgow, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Truro, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.